Regeneron Pharmaceuticals confirmed a quarterly dividend, released second quarter and half year 2026 results, and updated on recent share repurchases. The stock last closed at $784.36, which is 5.9% below a narrative fair value of $833.31. Its current P/E of 18.1x sits just above the US Biotechs industry average of 17.3x but well below a fair ratio of 26.1x. The company's pipeline includes recent or upcoming pivotal data in immunology, oncology, genetic medicines, and obesity, supporting future revenue growth. Key risks include pressure on EYLEA from competition and pricing, as well as setbacks from fianlimab and LAG 3 trial disappointments.
Regeneron Pharmaceuticals IncCompany confirmed dividend, released results, and updated on buybacks, with stock below fair value.
